FibroBiologics, Inc. (FBLG) Price & Analysis

Compare

102 Followers

FBLG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.53 - $4.41

Previous CloseN/A

Volume56.64K

Average Volume (3M)583.09K

Market Cap

$22.47M

Enterprise Value$25.97M

Total Cash (Recent Filing)$8.85M

Total Debt (Recent Filing)$10.78M

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Nov 18, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding41,889,140

10 Day Avg. Volume564,919

30 Day Avg. Volume583,092

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)24.04

Price to Sales (P/S)0.00

P/FCF Ratio-5.44

Enterprise Value/Market Cap1.16

Enterprise Value/Revenue46.88

Enterprise Value/Gross Profit365.77

Enterprise Value/Ebitda-2.07

Forecast

1Y Price Target

$7.00

Price Target Upside1220.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe therapeutic fibroblast platform is positioned to support upcoming clinical trials, having passed required safety testing and being in accordance with cGMP manufacturing protocols.

FinancingThe company has completed a $5M financing tranche to support research and development and clinical trials, which is a positive step for future growth.

Market PotentialFibroblasts have significant potential in regenerative medicine as they share a host of overlapping properties with stem cells, making them a potentially less expensive and more accessible cell therapy for patients.

Bears Say

CompetitionFibroBiologic’s drug candidate CYWC628 utilizes its fibroblast spheroid platform and in preclinical studies has demonstrated accelerated wound closure reaching 59% reduction in wound size vs. 35% for Grafix.

IND-Enabling WorkThe company plans to complete preclinical IND-enabling work for the fibroblast treatment of psoriasis by the end of 2025.

ValuationThe price target has been adjusted from $12 to $10 per share, indicating a change in valuation expectations.

FibroBiologics, Inc. News

FibroBiologics price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on FibroBiologics (FBLG) to $10 from $12 and...

3d ago

FBLG

FibroBiologics files patent application on generating multipotent cells

FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office, USPTO,...

11d ago

FBLG

FibroBiologics Reports Increased Losses Amid R&D Expansion

FibroBiologics, Inc. ( ($FBLG) ) has released its Q2 earnings. Here is a breakdown of the information FibroBiologics,...

3d ago

FBLG

Positive Outlook on FibroBiologics, Inc. Due to Strategic Positioning and Clinical Progress in Fibroblast-Based Therapies

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on FibroBiologics, Inc., with...

3d ago

FBLG

FibroBiologics Reduces Note Balances Through Conversions

FibroBiologics, Inc. ( ($FBLG) ) has provided an update. FibroBiologics, Inc. entered into a Standby Equity Purchase Agreement...

21d ago

FBLG

FibroBiologics announces advancement in its cartilage repair program

FibroBiologics (FBLG) announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochemistry and transcriptomic...

1M ago

FBLG

FibroBiologics Faces Nasdaq Delisting Notice

FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On July 1, 2025, FibroBiologics, Inc. received a notification...

1M ago

FBLG

FibroBiologics Secures $5M in Equity Purchase Agreement

FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On June 16, 2025, FibroBiologics, Inc. announced the closing...

2M ago

FBLG

FibroBiologics, Inc. Holds Annual Stockholders Meeting

FibroBiologics, Inc. ( ($FBLG) ) has issued an announcement. On June 12, 2025, FibroBiologics, Inc. held its Annual...

2M ago

FBLG

FibroBiologics Appoints Jason D. Davis as CFO

FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On June 9, 2025, FibroBiologics announced the appointment of...

2M ago

FBLG

FibroBiologics appoints Jason Davis as CFO

FibroBiologics (FBLG) announced the appointment of Jason Davis, CPA, as CFO, effective immediately. Davis most recently served as...

2M ago

FBLG

Promising Potential for FibroBiologics, Inc. in Regenerative Medicine with Innovative Fibroblast-Based Therapies

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on FBLG stock, giving a Buy rating yesterday....

3M ago

FBLG

Promising Developments at FibroBiologics: Buy Rating Reinforced Amid Upcoming Clinical Trials and Expanding Pipeline

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on FibroBiologics, Inc. (FBLG – Research Report)....

3M ago

FBLG

FibroBiologics CFO Robert Hoffman Resigns

FibroBiologics, Inc. ( ($FBLG) ) has provided an announcement. On May 2, 2025, Robert E. Hoffman announced his...

3M ago

FBLG

FBLG FAQ

What was FibroBiologics, Inc.’s price range in the past 12 months?

FibroBiologics, Inc. lowest stock price was $0.53 and its highest was $4.41 in the past 12 months.

What is FibroBiologics, Inc.’s market cap?

FibroBiologics, Inc.’s market cap is $22.47M.

When is FibroBiologics, Inc.’s upcoming earnings report date?

FibroBiologics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 102 days.

How were FibroBiologics, Inc.’s earnings last quarter?

FibroBiologics, Inc. released its earnings results on Jul 31, 2025. The company reported -$0.12 earnings per share for the quarter, the consensus estimate of -$0.12 by $0.

Is FibroBiologics, Inc. overvalued?

According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does FibroBiologics, Inc. pay dividends?

FibroBiologics, Inc. does not currently pay dividends.

What is FibroBiologics, Inc.’s EPS estimate?

FibroBiologics, Inc.’s EPS estimate is -0.11.

How many shares outstanding does FibroBiologics, Inc. have?

FibroBiologics, Inc. has 41,889,140 shares outstanding.

What happened to FibroBiologics, Inc.’s price movement after its last earnings report?

FibroBiologics, Inc. reported an EPS of -$0.12 in its last earnings report, expectations of -$0.12. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of FibroBiologics, Inc.?

Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.

FibroBiologics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-559.73%

Trailing 12-Months

Asset Growth

56.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

FibroBiologics, Inc.

FibroBiologics, Inc. (FBLG) is a biotechnology company focused on developing and commercializing advanced cellular therapies that leverage fibroblast cells for regenerative medicine. The company operates in the biotechnology sector, emphasizing the development of therapies for various medical conditions, including chronic diseases and degenerative disorders. FibroBiologics aims to harness the therapeutic potential of fibroblasts to address unmet medical needs and improve patient outcomes.

FibroBiologics, Inc. (FBLG) Earnings & Revenues

Historic Earnings Reports

FBLG Stock 12 Month Forecast

Average Price Target

$7.00

▲(1220.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,1.3692307692307693,2.0884615384615386,2.8076923076923075,3.526923076923077,4.246153846153846,4.9653846153846155,5.684615384615385,6.403846153846154,7.1230769230769235,7.842307692307693,8.561538461538461,9.28076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,1.1384615384615384,1.626923076923077,2.1153846153846154,2.603846153846154,3.092307692307692,3.5807692307692305,4.069230769230769,4.5576923076923075,5.046153846153846,5.5346153846153845,6.023076923076923,6.5115384615384615,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.9076923076923078,1.1653846153846155,1.4230769230769234,1.680769230769231,1.9384615384615387,2.1961538461538463,2.453846153846154,2.7115384615384617,2.9692307692307693,3.226923076923077,3.4846153846153847,3.742307692307693,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.03,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.62,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >